Literature DB >> 21685909

Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.

Bevan Tandon1, Loann Peterson, Juehua Gao, Beverly Nelson, Shuo Ma, Steven Rosen, Yi-Hua Chen.   

Abstract

Lymphoid-enhancer-binding factor 1 (LEF1), coupling with β-catenin, functions as a key nuclear mediator of WNT/β-catenin signaling, which regulates cell proliferation and survival. LEF1 has an important role in lymphopoiesis, and is normally expressed in T and pro-B cells but not mature B cells. However, gene expression profiling demonstrates overexpression of LEF1 in chronic lymphocytic leukemia, and knockdown of LEF1 decreases the survival of the leukemic cells. So far, the data on LEF1 expression in B-cell lymphomas are limited. This study represents the first attempt to assess LEF1 by immunohistochemistry in a large series (290 cases) of B-cell lymphomas. Strong nuclear staining of LEF1 was observed in virtually all neoplastic cells in 92 of 92 (100%) chronic lymphocytic leukemia/small lymphocytic lymphomas including two CD5- cases, with strongest staining in cells with Richter's transformation. LEF1 also highlighted the morphologically inconspicuous small lymphocytic lymphoma component in three composite lymphomas. All 53 mantle cell lymphomas, 31 low-grade follicular lymphomas and 31 marginal zone lymphomas, including 3 CD5+ cases, were negative. In 12 grade 3 follicular lymphomas, LEF1 was positive in a small subset (5-15%) of cells. Diffuse large B-cell lymphoma, however, demonstrated significant variability in LEF1 expression with overall positivity in 27 of 71 (38%) cases. Our results demonstrate that nuclear overexpression of LEF1 is highly associated with chronic lymphocytic leukemia/small lymphocytic lymphoma, and may serve as a convenient marker for differential diagnosis of small B-cell lymphomas. The expression of β-catenin, the coactivator of LEF1 in WNT signaling, was examined in 50 chronic lymphocytic leukemia/small lymphocytic lymphomas, of which 44 (88%) showed negative nuclear staining. The findings of universal nuclear overexpression of LEF1 but lack of nuclear β-catenin in the majority of chronic lymphocytic leukemia/small lymphocytic lymphoma suggest that the pro-survival function of LEF1 in this disease may be independent of WNT/β-catenin signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685909     DOI: 10.1038/modpathol.2011.103

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  22 in total

1.  Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.

Authors:  Aatur D Singhi; Mhammed Lilo; Ralph H Hruban; Kristi L Cressman; Kimberly Fuhrer; Raja R Seethala
Journal:  Mod Pathol       Date:  2014-03-21       Impact factor: 7.842

Review 2.  Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.

Authors:  Narittee Sukswai; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

3.  A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement.

Authors:  Kengo Takeuchi; Seiji Sakata; Reimi Asaka; Naoko Tsuyama; Akito Dobashi; Masaaki Noguchi
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

Review 4.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

5.  Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.

Authors:  Macarena I de la Fuente; Aya Haggiagi; Adrienne Moul; Robert J Young; Charif Sidani; Arnold Markoe; Francisco Vega; Lisa M DeAngelis; Izidore S Lossos
Journal:  Leuk Lymphoma       Date:  2016-09-21

6.  Identification of DNA-dependent protein kinase catalytic subunit as a novel interaction partner of lymphocyte enhancer factor 1.

Authors:  Atsushi Shimomura; Akihiko Takasaki; Ryuji Nomura; Nobuhiro Hayashi; Takao Senda
Journal:  Med Mol Morphol       Date:  2013-01-17       Impact factor: 2.309

Review 7.  Wnt Signaling in Hematological Malignancies.

Authors:  Stephanie Grainger; David Traver; Karl Willert
Journal:  Prog Mol Biol Transl Sci       Date:  2017-12-29       Impact factor: 3.622

8.  LEF-1 is a Sensitive Marker of Cribriform Morular Variant of Papillary Thyroid Carcinoma.

Authors:  Shalini Mohindra; Hany Sakr; Charles Sturgis; Deborah J Chute
Journal:  Head Neck Pathol       Date:  2017-12-14

Review 9.  The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.

Authors:  Steven H Swerdlow; Isinsu Kuzu; Ahmet Dogan; Stephan Dirnhofer; John K C Chan; Birgitta Sander; German Ott; Luc Xerri; Leticia Quintanilla-Martinez; Elias Campo
Journal:  Virchows Arch       Date:  2015-10-10       Impact factor: 4.064

10.  LEF-1: Diagnostic utility in distinguishing basaloid neoplasms of the salivary gland.

Authors:  Alessandra C Schmitt; Christopher C Griffith; Cynthia Cohen; Momin T Siddiqui
Journal:  Diagn Cytopathol       Date:  2017-10-03       Impact factor: 1.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.